Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

1, Number 1 Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs62732277

Full Text :

https://doi.org/10.1182/blood-2022-158501